Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.

Benralizumab reduced asthma exacerbations and improved lung function in patients with severe, eosinophilic asthma, according to results of the SIROCCO* and CALIMA** trials which were presented at the European Respiratory Society (ERS) International Congress 2016 held in London, UK.

The Role of Modern Second-generation Antihistamines in Allergic Rhinitis

25 Jul 2017

Allergic rhinitis (AR) is a common global health problem that poses a significant impact on the quality of life and productivity of affected patients. At the Ear, Nose and Throat (ENT) Summit 2017 held recently at Hilton Sentral, Kuala Lumpur, Malaysia, Associate Professor Marysia P Tiongco-Recto was invited by A. Menarini to deliver a lecture on the potential of modern second-generation antihistamines, particularly bilastine (Bilaxten®) in the management of AR.

Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.

Benralizumab reduced asthma exacerbations and improved lung function in patients with severe, eosinophilic asthma, according to results of the SIROCCO* and CALIMA** trials which were presented at the European Respiratory Society (ERS) International Congress 2016 held in London, UK.